Pharmaceutical research, driving advancements in drug development and treatment modalities, is intertwined with complex ethical considerations. In clinical trials, ethical frameworks emphasize the principles of informed consent, ensuring the welfare and rights of research participants, and maintaining scientific integrity. Before testing on humans, potential drugs undergo rigorous testing in laboratory settings (in vitro) and animal models (in vivo) to evaluate their safety, efficacy, and potential side effects. Researchers work on developing the most effective and safe form of the drug, considering factors like dosage form, route of administration, and stability. Discussions around equitable access to experimental treatments, especially in global clinical trials, underscore ethical imperatives related to justice and fairness. Addressing potential conflicts of interest, transparent reporting of research findings, and safeguarding the rights of vulnerable populations are integral to ethical practices in pharmaceutical research. As the landscape of drug discovery evolves, ethical discourse remains central to balancing the pursuit of scientific innovation with the ethical responsibilities to research participants and the broader community.
Title : Overview of augmented intelligence for nursing
Adele Webb, Strategic Education, Inc., United States
Title : Equity in action: Amplifying your voice in nursing leadership
Robin Adams Geiger, Ingenovis Health, United States
Title : The relationship between empowerment and quality of health among clients with chronic health conditions
Ismat Mikky, Bloomfield College of Montclair State University, United States
Title : Healthcare system sponsored CNA training program creates opportunity and increases workforce
John R Balcuk, Northwell Health Huntington Hospital, United States
Title : Pathway-Aligned degrees: A strategic solution to the global nursing shortage
Maureen Kroning, SUNY Empire State University, United States
Title : The importance of assessing the patient experience of hypersensitivity reaction
Kerry Hennessy, Dana Farber Cancer Institute, United States